A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading drugmakers in a field

SAN DIEGO — Since Herceptin’s approval in 1998, breast cancer has been reshaped from a near-term death sentence into — in many cases — a

Carvykti shows promise in patients before full-blown multiple myeloma: Researchers from Dana-Farber Cancer Institute shared that 20 patients with high-risk smoldering multiple myeloma all saw

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.